Replies to post #241892 on Biotech Values

[RNsidersbuying]

SBTX 3.21 - "The SBT8230 HBV program is a very long longshot, IMHO."

Aren't the vast majority of these small biotechs 'longshots'? So yes, I agree with you but with approx. $9 (mostly cash) BV at yearend, it would seem SBTX could close their doors today - and issue some $7+ to all shareholders...or a healthy double from Friday's close?

Note the ex-CEO owned 25.1% of the O/S at the April/21 DEF14A filing:

Peter Thompson, M.D.(7) 8,745,139 25.1%

https://docoh.com/filing/1671858/0001193125-21-126673/SBTX-DEF14A

Even in pennystocks, I've never seen a selloff this extreme in terms of HARDCASH-to-PPS...SBTX does appear to be a gimme of gimme's at this pps!